PYC Therapeutics Ltd
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atroph… Read more
PYC Therapeutics Ltd (PYC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.203x
Based on the latest financial reports, PYC Therapeutics Ltd (PYC) has a cash flow conversion efficiency ratio of -0.203x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-34.54 Million) by net assets (AU$170.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
PYC Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how PYC Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
PYC Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PYC Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
B.Grimm Power Public Company Limited
BK:BGRIM
|
0.092x |
|
Tellgen Corp
SHE:300642
|
0.024x |
|
Zhejiang Wellsun Intelligent Tech
SHE:300882
|
0.112x |
|
Hangzhou Fortune Gas Cryogenic Group Co. Ltd. A
SHG:603173
|
N/A |
|
Jiangsu Feymer Technology Co Ltd
SHG:688350
|
0.064x |
|
MARAVAI LIFESC.HLD.A -01
F:MAR
|
N/A |
|
Ginwa Enterprise Group Inc
SHG:600080
|
0.019x |
|
Qingdao NovelBeam Technology Co. Ltd. A
SHG:688677
|
0.013x |
Annual Cash Flow Conversion Efficiency for PYC Therapeutics Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of PYC Therapeutics Ltd from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$170.01 Million | AU$-51.56 Million | -0.303x | +36.30% |
| 2024-06-30 | AU$81.05 Million | AU$-38.59 Million | -0.476x | +44.55% |
| 2023-06-30 | AU$28.44 Million | AU$-24.42 Million | -0.859x | -58.47% |
| 2022-06-30 | AU$40.20 Million | AU$-21.78 Million | -0.542x | -147.78% |
| 2021-06-30 | AU$53.92 Million | AU$-11.79 Million | -0.219x | -14.86% |
| 2020-06-30 | AU$30.20 Million | AU$-5.75 Million | -0.190x | +76.60% |
| 2019-06-30 | AU$6.30 Million | AU$-5.13 Million | -0.814x | +80.02% |
| 2018-06-30 | AU$1.65 Million | AU$-6.71 Million | -4.072x | -1815.51% |
| 2017-06-30 | AU$8.86 Million | AU$-1.88 Million | -0.213x | +60.86% |
| 2016-06-30 | AU$5.83 Million | AU$-3.17 Million | -0.543x | +78.94% |
| 2015-06-30 | AU$962.03K | AU$-2.48 Million | -2.579x | -199.69% |
| 2014-06-30 | AU$3.72 Million | AU$-3.20 Million | -0.861x | +55.58% |
| 2013-06-30 | AU$1.19 Million | AU$-2.32 Million | -1.938x | -25.63% |
| 2012-06-30 | AU$2.69 Million | AU$-4.15 Million | -1.542x | -128.13% |
| 2011-06-30 | AU$4.35 Million | AU$-2.94 Million | -0.676x | -108.14% |
| 2010-06-30 | AU$-437.08K | AU$-3.63 Million | 8.302x | +509.05% |
| 2009-06-30 | AU$1.91 Million | AU$-3.88 Million | -2.030x | -9.99% |
| 2008-06-30 | AU$2.69 Million | AU$-4.97 Million | -1.845x | -31.11% |
| 2007-06-30 | AU$2.20 Million | AU$-3.09 Million | -1.407x | -5.96% |
| 2006-06-30 | AU$2.11 Million | AU$-2.81 Million | -1.328x | -476.72% |
| 2005-06-30 | AU$5.78 Million | AU$-1.33 Million | -0.230x | -549.11% |
| 2004-06-30 | AU$546.00K | AU$28.00K | 0.051x | -- |